Tempus

Chicago, United States Founded: 2015 • Age: 11 yrs Listed
AI-based precision medicine solutions for oncology are provided.

About Tempus

Tempus is a publicly listed company based in Chicago (United States) founded in 2015 by Eric Lefkofsky. AI-based precision medicine solutions for oncology are provided. It operates on a AI-as-a-Service, Data-as-a-Service, and Professional Services model in Healthcare and Technology sectors. Tempus has raised $1.05 billion across 9 funding rounds from investors including Google, T. Rowe Price and Franklin Templeton. The company has 3,157 employees. Tempus has completed 5 acquisitions, including Deep 6 AI, Mpirik and Highline SCIENCES. Tempus was last valued at $6.1 billion in June 2024. Its chief executive, as recorded, is Eric Lefkofsky. Its website tempus.com draws about 151 thousand monthly visits. Tempus offers products and services including Tempus One, Tempus Lens, Tempus xM, and Tempus Pixel. Its focus areas include Precision Medicine, AI-enabled Diagnostics, Artificial Intelligence and Healthcare AI. Its competitors include Personalis, CancerIQ and Perthera; 3 of its 3 listed competitors have raised funding.

Company details

Tempus is engaged in developing AI-enabled precision medicine solutions for healthcare providers, life sciences, and patients. The company operates in sectors such as oncology, neurology, psychiatry, cardiology, and radiology. Solutions offered include genomic profiling, clinical trial matching, real-world data analysis, and diagnostic imaging. Through extensive research and partnerships, Tempus is committed to accelerating personalized patient care and transforming drug development for pharmaceutical companies. Its technology integrates with electronic health records to enhance workflow and close care gaps.

  • Headquarters Chicago, United States
  • Employees 3,157
  • Founders Eric Lefkofsky
  • Stage Public
  • Sectors
    Healthcare
    Technology
  • Website category Health · Health Conditions and Concerns
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website tempus.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Tempus Ai, Inc.
Key Metrics
  • Annual Revenue
    $1.27 B (USD)
    83.41
    as on Dec 31, 2025
  • Net Profit
    -$245.03 M (USD)
    65.28
    as on Dec 31, 2025
  • EBITDA
    -$136.31 M (USD)
    79.07
    as on Dec 31, 2025
  • Total Equity Funding
    $1.05B (USD)

    in 9 rounds

  • Latest Funding Round
    $460M (USD), Post-IPO

    Jul 2026

  • Investors
    Google

    & 11 more

  • Employee Count
    3,157
  • Investments & Acquisitions
    Deep 6 AI

    & 4 more

Products & Services of Tempus

Tempus offers a comprehensive portfolio of products and services, including Tempus One, Tempus Lens, Tempus xM, and Tempus Pixel.

Tempus One
AI-enabled Assistant

AI assistant for healthcare providers and researchers.

Tempus Lens
Data Analysis Platform

Platform for accessing multimodal real-world data analysis.

Tempus xM
Liquid Biopsy Assay

Assay for monitoring immunotherapy response in cancers.

Tempus Pixel
Diagnostic Imaging

Imaging solutions for therapy response evaluation purposes.

Apps and channels of Tempus

its YouTube channel Tempus AI has 2.84K subscribers and 30 videos.

Tempus AI
YouTube 2.84K subscribers 30 videos Science & Technology
Open channel

Videos from Tempus

The most watched videos on Tempus's YouTube channel, Tempus AI (2.84K subscribers). Click a video to play it here.

Tempus Roadshow Clips (June 2024)
10.9K views
Tempus OS | The operating system for precision medicine innovation
4.3K views
Patient Story: Gordon | Tempus
2.6K views
Tempus xM | MRD and monitoring assays
2K views

More on Tempus AI.

Funding Insights of Tempus

Tempus has successfully raised a total of $1.05B across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $460 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.05B
  • Total Rounds 9
  • Last Round Post-IPO β€” $460M
  • First Round $70M

    (Sep 2017)

  • Investors Count 12

All 9 funding rounds of Tempus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2026$460MPost-IPO––
–
Oct 2022Series G––
–
Oct 2022Debt – Conventional––
–
Dec 2020$200MSeries G$8.1BGoogle
Mar 2020$100MSeries G–Baillie Gifford, Franklin Templeton Investments
–
May 2019$200MSeries F–Franklin Templeton Investments
Aug 2018$110MSeries E$2BT. Rowe Price, Baillie Gifford
Mar 2018$80MSeries D–New Enterprise Associates, Revolution
–
Sep 2017$70MSeries C–New Enterprise Associates, Revolution
–
Valuation history
DateValuationStage
Dec 2020$8.1Bβ€’β€’β€’β€’β€’β€’β€’β€’
Aug 2018$2Bβ€’β€’β€’β€’β€’β€’β€’β€’
Premium access

Full valuation and stage history of Tempus

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $6.1B (Jun 2024). 12 investors in total: 12 institutional.

Investors in Tempus

Tempus has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Google, T. Rowe Price and Franklin Templeton.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Private equity and venture capital fund focused on the healthcare sector
novoholdings.dkHellerup, Denmark
Venture capital investments are offered to startups by NEA.
nea.comMenlo Park, United States
Revolution is recognized as a D.C.-based investment firm.
revolution.comWashington, Dc, United States
Tech focused seed & early stage VC firm investing primarily in the US
lightbank.comChicago, United States
Venture capital investments are directed toward blockchain startups by Lemniscap.
lemniscap.comGeorge Town, Cayman Islands
Early-stage venture capital arm of SoftBank Group
sbvacorp.comSeoul, South Korea
saints-it.com
A technology company offering products and services, including search engine, cloud computing, advertising, email, productivity software, and more
1998google.comMountain View, United States
Diversified investment management services are provided by the firm.
1908bailliegifford.comEdinburgh, United Kingdom
Diversified investment management services are offered globally by the firm.
1947franklintempleton.comNew York, United States
Premium access

Investor details for Tempus

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Tempus

604 people are tracked at Tempus (208 in leadership, 5 in board & advisors, 391 in team); the tracked headcount is 3,157.

NameRoleGroup
Eric Lefkofsky
Founder & CEOLeadership
Catherine Igartua
Vice President Of Translational ResearchLeadership
Jonathan Dry
Vice President Pharma R&dLeadership
Maria Mikkelson
Senior Director, Atlanta Lab Systems And InformaticsLeadership
Shane Colley
CTOLeadership
Diane Flasch
Associate DirectorLeadership
Ryan Fukushima
Chief Operating OfficerLeadership
Melissa Chester
Senior Project DirectorLeadership
Arjun Ishwar
Director Omics SolutionsLeadership
Siqi Liu
Vice President Of Machine LearningLeadership
Dan S.
Associate Director - Scientific AffairsLeadership
Jane Patel
Director, Lab OperationsLeadership
Jim Rogers
CFOLeadership
Eric Ranes
Sr. Director Of Supply ChainLeadership
Meghan Degele
Sr. Director, Clinical Research PartnershipsLeadership
Kate Sasser
Chief Scientific OfficerLeadership
Shelley MacNeil
Director Of Data SolutionsLeadership
Christoff Coetzee
Senior Director: Process Engineering And AutomationLeadership
Darren Wozniak
Key Account Director - Research Services And CdxLeadership
Ira Klein
Vice President, Medical Affairs & Payer RelationsLeadership

584 more people are available in the full profile.

Premium access

Complete people profiles for Tempus

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Tempus

Tempus is a publicly listed company on the NASDAQ with ticker symbol TEM in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 Jun 2024
  • Listed onNASDAQ: TEM
  • Listed entityTempus AI, Inc.
  • Exchange sectorTechnology services
  • ISINUS88023B1035
  • Share price$68.22 (+0.34% on the day) · 2026-10-13
  • Market capitalisation$12.31B
  • EPS (diluted, trailing year)$-1.44
  • Volume (last session)4,157,626

Financials of Tempus

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$1.27B-$245.0M-$136.3M
2024$693.4M-$705.8M-$651.1M
2023$531.8M-$214.1M-$163.2M
2022$320.7M-$289.8M-$238.7M
2021$257.9M-$259.2M-$220.1M
Premium access

Detailed financial statements for Tempus

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Tempus

Tempus has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Deep 6 AI, Mpirik and Highline SCIENCES.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
AI-enabled tools for computational pathology and cancer diagnostics are provided.
paige.aiNew York, United States2018Aug 2025$81.25M
AI enabled solutions for clinical trials
deep6.aiPasadena, United States2013Mar 2025β€’β€’β€’β€’
Genetic testing is provided for clinical diagnostics and genomic services.
ambrygen.comAliso Viejo, United States1999Nov 2024$600M
Orthopedic care management platforms are provided for clinics and hospitals.
mpirik.comMilwaukee, United States2011Mar 2023β€’β€’β€’β€’
CRO focused on clinical development services for oncology drugs
highlinesciences.comSan Francisco, United States2018Feb 2022β€’β€’β€’β€’
Premium access

Complete acquisition details for Tempus

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Tempus

10 dated milestones of Tempus across 11 years, from founding to its latest funding, stage changes and deals.

  1. Founded Tempus is founded.
  2. Funding First funding round of $70.0M.
  3. Milestone Reaches Unicorn status.
  4. Acquisition Acquires Highline SCIENCES.
  5. Acquisition Acquires Mpirik.
  6. IPO Lists on the stock exchange (IPO).
  7. Acquisition Acquires Ambry Genetics.
  8. Acquisition Acquires Deep 6 AI.
  9. Acquisition Acquires PAIGE.
  10. Funding Latest funding round, Post-IPO, of $460.0M.

Competitors of Tempus

Tempus has 3 listed competitors in our database, 3 of them funded. They include Personalis, CancerIQ and Perthera.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
personalis.com2011Menlo Park, United States$87.3M310
Genomic sequencing and diagnosis software is provided for healthcare.
canceriq.com2013Chicago, United States$23.87M78
CancerIQ is focused on precision cancer prevention and care.
perthera.com2012Mclean, United States$17.02M13
Molecular cancer profiling is conducted via genomics and proteomics.
Premium access

Detailed competitors of Tempus

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Tempus

The website of Tempus (tempus.com) receives about 150.9K visits a month and ranks #320,246 among all websites worldwide, #11,224 in Health Conditions and Concerns.

  • Monthly visits
    150.9K

    ▲ 13.5% vs previous month

  • Unique visitors
    66.5K

    per month

  • Global rank
    #320,246

    among all websites

  • Category rank
    #11,224

    Health · Health Conditions and Concerns

Similar websites

Websites whose visitors overlap most with Tempus. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
tempusunlimited.org
tempusunlimited.org
100%
#102,804–
aruplab.com
92%
138.9K#300,732View details
castlebiosciences.com
92%
26.9K#985,933View details
cccnevada.com
92%
#2,017,364View details
foxchase.org
92%
111.1K#341,787View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 25 similar websites and full traffic analytics for Tempus

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 25 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Clinical IT & Data Platforms

3 companies that operate in the same segment as Tempus (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Employee health benefits are facilitated via a cloud-based platform.
2007Plymouth Meeting, Pennsylvania, United StatesUSD 228.3 M
Healthcare appointments are booked online via Zocdoc's platform.
2007New York, New York, United StatesUSD 425.97 MUSD 4.66 M1,365
Virtual physical therapy and digital pain care solutions are provided.
2015San Francisco, California, United StatesUSD 854.44 M1,746
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Tempus

Premium access

Complete news archive for Tempus

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tempus

Tempus was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Tempus is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.

Eric Lefkofsky is the CEO of Tempus, as recorded in our data. They have also founded this company.

Tempus is a funded company, having raised a total of $1.05B across 9 funding rounds to date. The company's 1st funding round was a Series C of $70M, raised on Sep 2017.

Tempus has 3,157 employees.

Annual revenue of Tempus is $1.27B as on Dec 31, 2025.

Tempus is engaged in developing AI-enabled precision medicine solutions for healthcare providers, life sciences, and patients. The company operates in sectors such as oncology, neurology, psychiatry, cardiology, and radiology. Solutions offered include genomic profiling, clinical trial matching, real-world data analysis, and diagnostic imaging. Through extensive research and partnerships, Tempus is committed to accelerating personalized patient care and transforming drug development for pharmaceutical companies. Its technology integrates with electronic health records to enhance workflow and close care gaps.

Tempus's top competitors include Personalis, CancerIQ and Perthera.

Tempus offers Tempus One, Tempus Lens, Tempus xM, and Tempus Pixel.

Yes, Tempus is publicly traded on NASDAQ under the ticker symbol TEM.

Tempus has made 5 acquisitions, including Deep 6 AI, Mpirik, and Highline SCIENCES.

Tempus has 12 investors. Key investors include Google, T. Rowe Price, Franklin Templeton, Baillie Gifford, and Novo Holdings.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available